Prognosis of cardiovascular events after implantation of a cardioverterdefibrillator in patients with chronic heart failure: the value of increasing concentration of endothelin-1 and soluble forms of ST2 protein in blood plasma

Prognosis of cardiovascular events after implantation of a cardioverterdefibrillator in patients with chronic heart failure: the value of increasing concentration of endothelin-1 and soluble forms of ST2 protein in blood plasma

Aim. The purpose of this study was to examine the association of increasing concentrations of endothelin-1 and soluble forms of ST2 protein (sST2) in the blood plasma of patients with chronic heart failure (CHF) who underwent implantation of a cardioverter-defibrillator, with the development of car...

Full description

Bibliographic Details
Main Authors:	A. T. Teplyakov, N. I. Tarasov, L. K. Isakov, E. V. Grakova, M. N. Sinkova, K. V. Kopieva, О. B. Garmaeva, O. N. Ogurkova, V. V. Kalyuzhin, E. V. Kalyuzhina
Format:	Article
Language:	English
Published:	Siberian State Medical University (Tomsk) 2018-09-01
Series:	Бюллетень сибирской медицины
Subjects:	хроническая сердечная недостаточность имплантируемый кардиовертер-дефибриллятор сердечно-сосудистые события прогноз биомаркеры эндотелин-1 растворимая форма белка st2
Online Access:	https://bulletin.ssmu.ru/jour/article/view/1293

Similar Items

Удаление электродов имплантированных систем. Состояние проблемы
by: О. Сапельников, et al.
Published: (2019-12-01)

Prediction role of a novel biomarker ST2 in risk assessment of adverse cardiovascular events in chronic heart failure with preserved and intermediate ejection fraction after myocardial revascularization
by: E. V. Grakova, et al.
Published: (2018-10-01)

Clinical use of the new biomarker ST2 in patients with chronic heart failure of ischemic genesis: an exercise test
by: E. V. Grakova, et al.
Published: (2019-09-01)

Подкожные кардиовертеры-дефибрилляторы в сравнении с трансвенозными: 6-месячное наблюдение
by: А.В. Верещагина, et al.
Published: (2023-03-01)

A case of “non-compact myocardium” cardiomyopathy diagnosed and treated by means of implantable cardioverter-defibrillators
by: И. Е. Доровских, et al.
Published: (2016-11-01)

POSSIBILITY AND NECESSITY OF CATHETER ABLATION OF VENTRICULAR ARRHYTHMIAS IN PATIENTS WITH ISCHEMIC HEART DISEASE AND IMPLANTED CARDIOVERTERDEFIBRILLATOR
by: G. A. Gromyko, et al.
Published: (2018-01-01)

Remote monitoring of chronic noncommunicable diseases: potential in the COVID-19 pandemic
by: O. S. Kobyakova, et al.
Published: (2022-04-01)

Analysis of arrhythmic episodes in patients with implanted cardioverter defibrillators and a high risk of sudden cardiac death
by: A. S. Postol, et al.
Published: (2019-11-01)

CD40 ligand level – vascular inflammation activity and long6term prognosis in coronary heart disease patients
by: O. P. Shevchenko, et al.
Published: (2008-02-01)

Ventricular arrhythmias in ischemic versus nonischemic chronic heart failure. Is the equal sign between arrhythmia mechanisms and treatment strategies applicable?
by: R. D. Kurbanov, et al.
Published: (2011-03-01)

Adherence to therapy and the risk of cardiovascular events in patients with heart failure: data from the outpatient registry
by: E. T. Guseinova, et al.
Published: (2022-11-01)

CURRENT RECOMMENDATIONS ON RISK STRATIFICATION AND SUDDEN CARDIAC DEATH PREVENTION IN PATIENTS WITH HYPERTROPHIC CARDIOMYOPATHY (BASED ON THE 2011 RECOMMENDATIONS BY THE AMERICAN COLLEGE OF CARDIOLOGY / AMERICAN HEART ASSOCIATION)
by: E. V. Privalova, et al.
Published: (2013-02-01)

Heart Transplantation as a Treatment Method for Refractory Heart Failure due to Post-myocarditis Dilated Cardiomyopathy: a Clinical Case
by: Larisa A. Balykova, et al.
Published: (2019-06-01)

Role of stimulating growth factor 2 and galectin-3 in predicting the ventricular tachyarrhythmias in patients with ischemic cardiomyopathy
by: T. A. Atabekov, et al.
Published: (2021-05-01)

Rational pharmacotherapy of chronic heart failure with increased endothelin-1 activity: beta-adrenoblocker nebivolol place
by: L. I. Olbinskaya, et al.
Published: (2007-02-01)

PREDICTIVE VALUE OF CARDIAC CACHEXIA IN CHRONIC HEART FAILURE
by: E. S. Drobysheva, et al.
Published: (2016-08-01)

METABOLOMIC APPROACHES IN STUDYING OF CARDIOVASCULAR DISEASES
by: A. A. Аbdullaev, et al.
Published: (2021-03-01)

СИНДРОМ БРУГАДА
by: Виктор Николаевич Федорец, et al.
Published: (2022-01-01)

Prognostic value of heart failure biomarkers in the assessment of cardiac dysfunction in the fetus and newborn
by: O. A. Savchenko, et al.
Published: (2021-05-01)

Valid cardiac biochemical markers. Part II
by: N. G. Gumanova, et al.
Published: (2020-11-01)

Advanced heart failure
by: V. V. Kalyuzhin, et al.
Published: (2021-04-01)

Perioperative assessment of troponin level in the non-cardiac interventions: is there such a need?
by: A. N. Sumin
Published: (2015-11-01)

Prognostic significance of atherosclerosis of one or two vascular systems in patients with high and very high cardiovascular risk
by: V. V. Genkel, et al.
Published: (2021-03-01)

Effect of β-blocker therapy on the level soluble ST2 protein in the blood serum in patients with heart failure with preserved and mildly reduced ejection fraction
by: E. V. Grakova, et al.
Published: (2022-04-01)

ДИСФУНКЦИЯ ЭНДОТЕЛИЯ ПРИ СЕРДЕЧНО-СОСУДИСТЫХ ЗАБОЛЕВАНИЯХ: ФАКТОРЫ РИСКА, МЕТОДЫ ДИАГНОСТИКИ И КОРРЕКЦИИ
by: E.N. Vorobyeva, et al.
Published: (2016-03-01)

THE EFFICACY OF HIGH-DOSE SIMVASTATIN IN ACUTE PERIOD OF ISCHEMIC STROKE
by: V. V. Yakusevich, et al.
Published: (2015-12-01)

MACITENTAN: THE EVOLUTION OF THE CLASS ENDOTHELIN RECEPTOR ANTAGONISTS TO IMPROVE EFFICACY AND SAFETY OF PAH TREATMENT
by: T. V. Martynuk, et al.
Published: (2013-06-01)

NEW OPPORTUNITIES FOR PREVENTIVE THERAPY WITH STATINS DURING CHD PATIENTS’ REHABILITATION, WITH CLINICAL SIGNS OF MODERATE CHF: EFFECTIVENESS OF ROSUVASTATIN AND EZETIMIBE
by: N. I. Tarasov, et al.
Published: (2016-06-01)

Valid cardiac biomarkers. Part I
by: V. A. Metelskaya, et al.
Published: (2020-09-01)

Interrelations of quantitative and qualitative characteristics of productivity of the new peas lines
by: A. R. Ashiev, et al.
Published: (2019-03-01)

EARLY MARKERS OF PROGRESSION OF HEART FAILURE AND APOPTOSIS: THEIR ROLE IN PREDICTING THE RISK OF ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH PRIOR MYOCARDIAL INFARCTION
by: A. T. Teplyakov, et al.
Published: (2016-03-01)

Risk of fatal and non-fatal cardiovascular events in men aged 25-44 in the city of Novosibirsk. Cohort study
by: E. V. Stryukova, et al.
Published: (2023-02-01)

Nebivolol effects on myocardial remodelling, inflammation markers and endothelial dysfunction in chronic heart failure patients with or without Type 2 diabetes mellitus
by: Yu. N. Belenkov, et al.
Published: (2011-02-01)

The role of IL-33/ST2 system in the modulation of the immune response in infective endocarditis (a literature review)
by: M. A. Asanov, et al.
Published: (2020-07-01)

The Effect of Anthocyanins on Microcirculation and Retrobulbar Blood Flow in Ocular Pathology
by: T. N. Kiseleva, et al.
Published: (2019-10-01)

Pathogenesis of chronic heart failure: change of dominating paradigm
by: V. V. Kalyuzhin, et al.
Published: (2007-12-01)

The prognostic value of the NT-proBNP biomarkers and Fas ligand in assessing the risk of cardiotoxicity of anthracycline chemotherapy
by: A. T. Teplyakov, et al.
Published: (2019-03-01)

Growth Differentiation Factor-15 (GDF-15) is a Biological Marker in Heart Failure
by: A. M. Alieva, et al.
Published: (2023-01-01)

Contribution of cardio-ankle vascular index to prediction of cardiovascular events in the adult urban population: data from the ESSE-RF study (Tomsk)
by: A. R. Zairova, et al.
Published: (2021-09-01)

Osteoprotegerin is a new independent predictor of the progression of cardiovascular pathology: chronic heart failure associated with type 2 diabetes and osteoporosis
by: A. T. Teplyakov, et al.
Published: (2018-12-01)